SKYE Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (28 birž. 2024 @ 23:00):
Our systems believe the stock currently is undervalued by 0.22% compare to its pairs and should correct upwards.

Skye Bioscience, Inc., a biopharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases...

Stats
Šios dienos apimtis	2.09M
Vidutinė apimtis	132 919
Rinkos kapitalizacija	224.82M
EPS	$-0.180 ( Q1 \| 2024-05-10 )
Kita pelno data	( $-0.200 ) 2024-08-05
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.920 (Sector) 0 (Industry) 0
ATR14	$0.0360 (0.45%)

ACUT 16.78%

AIMD -3.89%

AKABY 0.00%

AOBI 0.00%

ARNI 417.24%

BETRF 0.00%

BRAXF 7.14%

BVNRY -7.81%

CLVLY -2.39%

COEP 1.05%

CPMV 0.00%

CRXM 0.00%

CSLLY 0.20%

ERGO 0.00%

GSTC 0.00%

IPCIF 0.00%

LVCLY 0.00%

MLCT 2.63%

NPTX 0.00%

NUGX 0.00%

OBMP -37.10%

OCEL -0.27%

ODTC 0.00%

OTLC 6.45%

PFND 0.00%

PROT 0.00%

PVCT 1.11%

QSAM -99.95%

RGBP 10.45%

RGBPP 0.00%

RSPI 8.11%

SIGY 0.00%

SILO 1.01%

SKYE 10.33%

SNNAQ 0.00%

SPHRY 0.00%

UCBJY 0.39%

USRM 0.00%

VGLS 100.00%

VICP 59.29%

WXXWY -1.02%

Insider Trading

Date	Person	Action	Amount	type
2024-03-13	5am Partners Vii, Llc	Buy	450 000	Common Stock
2024-03-13	Schwab Andrew J.	Buy	450 000	Common Stock
2024-02-29	Grayson Paul A.	Buy	100 000	Common Stock
2024-02-29	Grayson Paul A.	Buy	35 000	Stock Option (Right to Buy)
2024-02-29	Charych Deborah H.	Buy	35 000	Stock Option (Right to Buy)

INSIDER POWER
98.85
Last 83 transactions
Buy: 1 749 377 489 \| Sell: 16 641 486

Koreliacija (AI algo v.1.1b): Undervalued: 0.22% $8.05 paired level. (Algoritmas realiuoju laiku stebi didžiausią koreliaciją turinčių akcijų pokyčius ir suteikia momentinę informaciją)

Tūris Koreliacija

Ilgas: -0.17 (neutral)

Trumpas: 0.40 (neutral)

Signal:(39.609) Neutral

Skye Bioscience, Inc. Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Skye Bioscience, Inc. Koreliacija - Valiuta/Žaliavos

-0.34
( neutral )

-0.52
( weak negative )

0.00
( neutral )

-0.47
( neutral )

0.20
( neutral )

0.54
( weak )

Skye Bioscience, Inc. Finansinės ataskaitos

Annual	2023
Pajamos:	$0
Bruto pelnas:	$-124 251 (0.00 %)
EPS:	$-5.37

FY	2023
Pajamos:	$0
Bruto pelnas:	$-124 251 (0.00 %)
EPS:	$-5.37

FY	2022
Pajamos:	$0
Bruto pelnas:	$-114 998 (0.00 %)
EPS:	$-9.82

FY	2021
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-0.0200

Financial Reports:

No articles found.

Skye Bioscience, Inc. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Skye Bioscience, Inc.

Skye Bioscience, Inc., a biopharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100, which is in Phase I trials for the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 that is in preclinical trials to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. was founded in 2012 and is headquartered in San Diego, California.